Lindsey Marie  Hartley net worth and biography

Lindsey Hartley Biography and Net Worth

CFO of AxoGen

Lindsey Hartley has over 19 years of financial leadership experience, with significant expertise in corporate finance, accounting and financial reporting within the healthcare and medical device sectors.

Ms. Hartley joined Axogen in October 2021 as Vice President, Corporate Controller, prior to being promoted to Chief Financial Officer in May 2025. Prior to Axogen, she served as VP of Finance, Accounting and Human Strategy at VERO Biotech, an emerging biotechnology company focused on innovative nitric oxide delivery systems. Earlier in her career, Ms. Hartley held controller positions at Brookhaven Medical, a medical device manufacturing company specializing in peripheral vascular and regenerative medicine products and held management roles at Bluegreen Vacations and as an audit manager at EY.

Ms. Hartley holds a Bachelor of Science in Accounting from the University of South Florida and is a Certified Public Accountant.

What is Lindsey Marie Hartley's net worth?

The estimated net worth of Lindsey Marie Hartley is at least $1.10 million as of December 15th, 2025. Hartley owns 31,376 shares of AxoGen stock worth more than $1,098,788 as of February 3rd. This net worth approximation does not reflect any other investments that Hartley may own. Learn More about Lindsey Marie Hartley's net worth.

How do I contact Lindsey Marie Hartley?

The corporate mailing address for Hartley and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Lindsey Marie Hartley's contact information.

Has Lindsey Marie Hartley been buying or selling shares of AxoGen?

Lindsey Marie Hartley has not been actively trading shares of AxoGen in the last ninety days. Most recently, Lindsey Marie Hartley sold 14,812 shares of the business's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $29.86, for a transaction totalling $442,286.32. Following the completion of the sale, the chief financial officer now directly owns 31,376 shares of the company's stock, valued at $936,887.36. Learn More on Lindsey Marie Hartley's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 12/16/2025.

Lindsey Marie Hartley Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2025Sell14,812$29.86$442,286.3231,376View SEC Filing Icon  
12/8/2025Sell14,387$31.56$454,053.7231,376View SEC Filing Icon  
See Full Table

Lindsey Marie Hartley Buying and Selling Activity at AxoGen

This chart shows Lindsey Marie Hartley's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $35.01
Low: $34.21
High: $35.93

50 Day Range

MA: $31.65
Low: $27.69
High: $35.02

2 Week Range

Now: $35.01
Low: $9.22
High: $36.00

Volume

499,774 shs

Average Volume

1,040,263 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1